Zydus Cadila has received the final approval from the USFDA to market Dutasteride and Tamsulosin Hydrochloride Capsules, O.Smg/0.4 mg. The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Shares of the company gained Rs 1.7, or 0.48%, to trade at Rs 359.25. The total volume of shares traded was 30,500 at the BSE (10.51 a.m., Friday).